Strengthening the U.S. Drug Safety System
Print This
September 22 -- A lack of clear regulatory authority, chronic underfunding, organizational problems, and scarcity of data hamper the U.S. Food and Drug Administration’s ability to evaluate and address the safety of prescription drugs after they have reached the market, according to a new report from the Institute of Medicine. The report recommends steps to strengthen FDA’s authority and enforcement tools to help protect the health of the public.
